Tobam trimmed its position in  Hologic, Inc. (NASDAQ:HOLX – Get Rating) by 49.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,074 shares of the medical equipment provider’s stock after selling 1,996 shares during the period. Tobam’s holdings in Hologic were worth $155,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Romano Brothers AND Company purchased a new position in  Hologic in the fourth quarter worth about $25,000.  Whittier Trust Co. raised its stake in shares of  Hologic by 90.0% in the fourth quarter. Whittier Trust Co. now owns 380 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 180 shares during the period.  Salem Investment Counselors Inc. raised its stake in shares of  Hologic by 163.9% in the second quarter. Salem Investment Counselors Inc. now owns 549 shares of the medical equipment provider’s stock worth $38,000 after buying an additional 341 shares during the period.  Toth Financial Advisory Corp bought a new position in shares of  Hologic in the fourth quarter worth about $45,000.  Finally, General Partner Inc. bought a new position in shares of  Hologic in the fourth quarter worth about $49,000. 95.17% of the stock is owned by hedge funds and other institutional investors.

HOLX opened at $82.51 on Wednesday. The firm has a market cap of $20.34 billion, a price-to-earnings ratio of 21.05, a PEG ratio of 1.48 and a beta of 1.00. The company has a current ratio of 4.21, a quick ratio of 3.50 and a debt-to-equity ratio of 0.55. Hologic, Inc. has a 12 month low of $59.78 and a 12 month high of $86.65. The stock has a fifty day moving average price of $80.89 and a 200-day moving average price of $76.48.

Hologic (NASDAQ:HOLX – Get Rating) last announced its earnings results on Wednesday, February 1st. The medical equipment provider reported $1.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.17. Hologic had a return on equity of 25.12% and a net margin of 22.17%. The company had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same period in the prior year, the company posted $2.17 EPS. The firm’s quarterly revenue was down 27.0% compared to the same quarter last year.  As a group, equities research analysts anticipate that  Hologic, Inc. will post 3.74 earnings per share for the current fiscal year.

Several research firms have recently commented on HOLX. Raymond James raised their price objective on Hologic from $80.00 to $95.00 and gave the stock an “outperform” rating in a research note on Thursday, February 2nd. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a research note on Friday, April 14th. Mizuho lifted their target price on Hologic from $90.00 to $92.00 in a research note on Tuesday. Citigroup lifted their target price on Hologic from $75.00 to $85.00 and gave the company a “neutral” rating in a research note on Thursday, February 2nd. Finally, Cowen lifted their target price on Hologic from $86.00 to $95.00 and gave the company an “outperform” rating in a research note on Thursday, February 2nd. Eight analysts have rated the stock with a hold rating and eight have issued  a buy rating to the company. Based on data from MarketBeat, Hologic presently has a consensus rating of “Moderate Buy” and an average price target of $84.23.

In other Hologic news, insider Benjamin Jordan Cohn sold 9,128 shares of the business’s stock in a transaction dated Tuesday, February 7th. The stock was sold at an average price of $85.28, for a total transaction of $778,435.84. Following the sale, the insider now owns 14,298 shares in the company, valued at approximately $1,219,333.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.66% of the stock is currently owned by corporate insiders.

Hologic, Inc engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery.

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.